MTEM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases...

Stats
今日成交量	68 803.00
平均成交量	64 717.00
市值	9.16M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.970 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0330 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Biotech Target N V	Buy	250 000	Common Stock
2024-04-02	Biotech Target N V	Buy	769 334	Common Warrants (right to buy)
2024-04-02	Biotech Target N V	Buy	134 667	Prefunded Warrants (right to buy)
2024-04-02	Lalande Kevin M.	Buy	1 154 154	Warrants (Right to Buy)
2024-04-02	Lalande Kevin M.	Buy	402 077	Pre-Funded Warrants (Right to Buy)

INSIDER POWER
99.93
Last 98 transactions
Buy: 16 322 736 \| Sell: 222 785

音量相关性

長: 0.01 (neutral)

短: -0.59 (weak negative)

Signal:(58.538) Neutral

Molecular Templates Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Molecular Templates Inc 相关性 - 货币/商品

-0.33
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.41
( neutral )

0.32
( neutral )

Molecular Templates Inc 财务报表

Annual	2023
营收:	$57.31M
毛利润:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2023
营收:	$57.31M
毛利润:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2022
营收:	$19.75M
毛利润:	$11.95M (60.51 %)
EPS:	$-24.69

FY	2021
营收:	$38.70M
毛利润:	$0.00 (0.00 %)
EPS:	$1.690

Financial Reports:

No articles found.

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.